Karimi, M. and Solati, N. and Ghasemi, A. and Estiar, M.A. and Hashemkhani, M. and Kiani, P. and Mohamed, E. and Saeidi, A. and Taheri, M. and Avci, P. and Aref, A.R. and Amiri, M. and Baniasadi, F. and Hamblin, M.R. (2015) Carbon nanotubes part II: A remarkable carrier for drug and gene delivery. Expert Opinion on Drug Delivery, 12 (7). pp. 1089-1105.
Full text not available from this repository.Abstract
Introduction: Carbon nanotubes (CNT) have recently been studied as novel and versatile drug and gene delivery vehicles. When CNT are suitably functionalized, they can interact with various cell types and are taken up by endocytosis.Areas covered: Anti-cancer drugs cisplatin and doxorubicin have been delivered by CNT, as well as methotrexate, taxol and gemcitabine. The delivery of the antifungal compound amphotericin B and the oral administration of erythropoietin have both been assisted using CNT. Frequently, targeting moieties such as folic acid, epidermal growth factor or various antibodies are attached to the CNT-drug nanovehicle. Different kinds of functionalization (e.g., polycations) have been used to allow CNT to act as gene delivery vectors. Plasmid DNA, small interfering RNA and micro-RNA have all been delivered by CNT vehicles. Significant concerns are raised about the nanotoxicology of the CNT and their potentially damaging effects on the environment.Expert opinion: CNT-mediated drug delivery has been studied for over a decade, and both in vitro and in vivo studies have been reported. The future success of CNTs as vectors in vivo and in clinical application will depend on achievement of efficacious therapy with minimal adverse effects and avoidance of possible toxic and environmentally damaging effects. © 2015 Informa UK, Ltd.
| Item Type: | Article |
|---|---|
| Additional Information: | cited By 44 |
| Depositing User: | eprints admin |
| Date Deposited: | 02 Jul 2018 08:12 |
| Last Modified: | 02 Jul 2018 08:12 |
| URI: | http://eprints.iums.ac.ir/id/eprint/4860 |
Actions (login required)
 |
View Item |
